Thermo Fisher, AstraZeneca to develop NGS companion diagnostics

By LabPulse.com staff writers

September 1, 2021 -- Thermo Fisher Scientific and AstraZeneca plan to co-develop companion diagnostics based on next-generation sequencing (NGS) to support targeted therapies.

Their multiyear, global deal will help support AstraZeneca's therapy portfolio. Over 90% of AstraZeneca's clinical pipeline is targeted precision medicine therapies covering a range of therapeutic areas.

More than ever, NGS-based companion diagnostics are used to match patients with new therapies for cancer and other diseases, Thermo Fisher said. The company offers the only globally distributable NGS companion diagnostic approved and reimbursed by government and commercial insurers in more than 15 countries, including the U.S., it added.

FDA clears Thermo Fisher's new blood test for lupus
The U.S. Food and Drug Administration (FDA) cleared Thermo Fisher Scientific's blood test for diagnosing systemic lupus erythematosus, the most common...
Thermo Fisher secures EUA for 2 new COVID-19 tests
The U.S. Food and Drug Administration has granted emergency use authorization (EUA) to Thermo Fisher Scientific for two new COVID-19 tests, TaqPath COVID-19...
Thermo Fisher announces new suite of assays
Thermo Fisher Scientific announced a new suite of Ion Torrent Oncomine immune repertoire assays designed to detect potentially malignant clones of T cells...
Grail to collaborate with top companies for MRD detection
Cancer diagnostics startup Grail has announced collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate the ability of Grail's methylation-based...
Lynparza PARP approval opens door to more pancreatic cancer testing
Approval of the drug olaparib (Lynparza, Merck/AstraZeneca) by the U.S. Food and Drug Administration at the end of 2019 paves the way for more testing...

Copyright © 2021 LabPulse.com

Last Updated np 9/1/2021 4:13:45 PM